Taketo
Kenji Taketo, Tokyo JP
Patent application number | Description | Published |
---|---|---|
20120026183 | VISUAL FIELD IMAGE DISPLAY DEVICE FOR EYEGLASSES AND METHOD FOR DISPLAYING VISUAL FIELD IMAGE FOR EYEGLASSES - A visual field image display device for spectacles capable of displaying a retinal image by simulation corresponding to change even in visual line direction. A visual field image display device for spectacles adapted to display a retinal image seen when wearing a progressive-addition lens by simulation includes: an image processing section adapted to create the retinal image by performing a processing of adding blur and distortion to data of an original image in a visual field corresponding to the direction of a visual line of an eye of a person in a state where the person wears the progressive-addition lens, wherein the blur and distortion correspond to a passing point of the visual line on the progressive-addition lens; and a display section adapted to display the retinal image created by the image processing section. | 02-02-2012 |
Makoto Taketo, Kyoto JP
Patent application number | Description | Published |
---|---|---|
20090208486 | Pharmaceutical composition comprising cxcr3 inhibitor - A pharmaceutical composition for the treatment of cancer of which survival and/or metastasis is under the influence of signal transduction mediated by a chemokine receptor CXCR3, which comprises an agent to inhibit CXCR3, and a method of treatment and diagnosis of such cancer. | 08-20-2009 |
Makoto Taketo, Kyoto-Shi, Kyoto JP
Patent application number | Description | Published |
---|---|---|
20160103133 | METHOD FOR DETERMINING PROGNOSIS OF CANCER - The present invention relates to a method for determining prognosis of cancer in a subject, which comprises the step of detecting phosphorylation of a tyrosine residue at position 2681 of TRIO in a sample obtained from the subject. | 04-14-2016 |
Makoto Mark Taketo, Kyoto JP
Patent application number | Description | Published |
---|---|---|
20100255041 | REMEDY FOR THE TREATMENT OF CARDIO-VASCULAR DISEASES OR DISORDERS - Disclosed is the use of inhibitors of β-catenin expression or activity or modulators downregulating β-catenin expression or activity for the treatment of cardiovascular diseases or disorders and their use in the treatment of cardiovascular diseases and disorders, such as heart failure syndrome. The use of those agents resulted in particular in cardiomyocyte differentiation of endogenous cardiac stem cells. | 10-07-2010 |